Operational support company Nimbl has released a 2026 Flight Department Prep Checklist, shown below, to help operators ...

BMS Group has expanded its footprint across the Middle East, North Africa and South Asia with the launch of a new operation in Dubai and a strategic partnership in India. The moves form part of the ...

(Rockville, Maryland, December 9th, 2025) - As operators approach the new year, Nimbl is offering guidance on how to stay ahead of flight operation responsibilities and execute a 2026 plan that will ...

With FDA approval to treat marginal zone lymphoma (MZL), Bristol Myers Squibb’s Breyanzi has become the first CAR-T therapy in the indication, as well as the first CAR-T to reach the market for five ...

Marc Santos is a Guides Staff Writer from the Philippines. He's a seasoned writer with over four years of industry experience, and he is an enjoyer of all things difficult in gaming. If Marc's not ...

In a filing with the New Jersey Department of Labor & Workforce Development, Merck said it expects to cut 204 positions at its headquarters in Rahway between February and May 2026. This marks the ...

Jake Fillery is an Evergreen Editor for Game Rant who has been writing lists, guides, and reviews since 2022. With thousands of engaging articles and guides, Jake loves conversations surrounding all ...

FRANKFURT, Nov 3 (Reuters) - Germany's BioNTech (22UAy.DE), opens new tab on Monday lifted its 2025 revenue guidance after receiving initial payments from its new partner Bristol Myers Squibb (BMY.N), ...

Bristol Myers Squibb is shedding two clinical programs from its in-house pipeline, one from its 2023 Mirati buyout and another from a partnership with U.K. biotech Exscientia, now known as Recursion.

Nearly 4,500 Tesla Model 3 and Model Y owners in South Korea have complained about battery malfunctions that prevent charging. The problem, which primarily affects 2021 models, has drawn the scrutiny ...

The stars have aligned for Bristol Myers Squibb and Orbital Therapeutics. Pushing deeper into in vivo cell therapies, BMS has agreed to pay $1.5 billion to buy the biotech for a pipeline led by a ...